Dried Blood Spot Collection Cards Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Card Type (Whatman 903, Ahlstrom 226, FTA, Others), By Application (New-born Screening (NBS), Infectious Disease Testing, Therapeutic Drug Monitoring, Forensics, Others), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), By Region 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 421.27 Million
CAGR (2026-2031)	4.94%
Fastest Growing Segment	Whatman 903
Largest Market	North America
Market Size (2031)	USD 562.61 Million

Market Overview

The Global Dried Blood Spot Collection Cards Market will grow from USD 421.27 Million in 2025 to USD 562.61 Million by 2031 at a 4.94% CAGR. Dried blood spot (DBS) collection cards are absorbent cellulose or polymer-based devices designed to capture and preserve capillary blood samples for bioanalysis. The market is primarily propelled by the global expansion of newborn screening programs and the increasing adoption of serological surveillance for infectious diseases. These cards offer distinct logistical advantages, including reduced shipping costs and stability at ambient temperatures, which are critical for decentralized sampling. According to the Association of Public Health Laboratories, in 2024, the Newborn Screening Quality Assurance Program distributed nearly one million dried blood spot reference materials to laboratories globally, illustrating the substantial reliance on these tools for diagnostic accuracy.

However, market expansion faces significant impediments regarding sample quality variability. The hematocrit effect, where differing blood viscosity alters the spread and volume of the sample on the paper, remains a primary technical challenge complicating quantitative analysis and regulatory standardization.

Key Market Drivers

The expansion of mandatory newborn screening programs constitutes a primary driver for the Global Dried Blood Spot (DBS) Collection Cards Market, as these devices serve as the foundational tool for detecting congenital disorders in public health initiatives. Governments and health organizations are increasingly broadening screening panels to include complex genetic conditions, necessitating a consistent supply of standardized collection matrices to support high-throughput diagnostics. This trend towards comprehensive genomic profiling is exemplified by major industry collaborations; according to Revvity, in March 2025, the company expanded its partnership with Genomics England to screen up to 100,000 newborns for rare genetic disorders, directly influencing the demand for specialized collection solutions. Furthermore, the sheer operational scale of these mandates ensures a stable baseline for market volume. According to the Oregon Newborn Bloodspot Screening Program's 2024 Annual Report, the laboratory tested 124,704 samples in 2024 alone, illustrating the substantial and continuous reliance on DBS cards within state-level disease surveillance infrastructure.

Concurrently, the rising adoption of remote patient monitoring and a growing preference for minimally invasive sampling methodologies are diversifying the market beyond pediatric applications. DBS cards are being rapidly integrated into decentralized clinical trials and anti-doping protocols, offering a patient-centric alternative to traditional phlebotomy that eliminates the need for cold-chain logistics and professional technicians. The reduced biological burden on subjects significantly enhances participation and compliance in these remote settings. According to the Canadian Centre for Ethics in Sport, in July 2025, the volume of blood collected with dried blood spot devices is approximately 25 times less than a venous blood draw, a critical factor driving their acceptance for self-sampling. This capability effectively bridges the gap between home-based participants and central laboratories, expanding the utility of DBS technology into therapeutic drug monitoring and longitudinal health studies.

Download Free Sample Report

Key Market Challenges

Sample quality variability, specifically the hematocrit effect, restricts the expansion of the Global Dried Blood Spot Collection Cards Market. This technical limitation causes blood with different viscosity levels to spread unevenly across the collection paper, resulting in non-uniform sample volumes within a fixed punch diameter. Such inconsistency undermines the reliability required for quantitative bioanalysis, hindering laboratories from meeting the stringent precision standards mandated by regulatory agencies. Consequently, potential adopters in pharmaceutical development and therapeutic drug monitoring remain hesitant to transition from liquid blood to dried blood spots for critical quantitative applications.

The reluctance to adopt these devices is reinforced by the operational risks associated with high-volume testing environments where accuracy is paramount. According to the Association of Public Health Laboratories, in 2024, public health laboratories in the United States screened nearly 3.6 million newborns. In a landscape demanding such extensive processing capabilities, any device limitation that introduces analytical error or necessitates sample re-testing creates unacceptable logistical burdens. Therefore, the hematocrit issue directly limits market growth by confining the technology primarily to qualitative screening rather than enabling its expansion into broader diagnostic sectors.

Key Market Trends

Integration with automated sample processing and mass spectrometry workflows is fundamentally reshaping the Global Dried Blood Spot Collection Cards Market by removing the bottleneck of manual extraction. Laboratories are increasingly pairing high-throughput robotics with sensitive liquid chromatography-mass spectrometry (LC-MS/MS) systems to process collection cards with the same speed and precision as liquid plasma. This shift allows for the multiplexed analysis of proteins and metabolites at scale, moving the technology beyond simple qualitative screening into complex bioanalysis. According to Vitas Analytical Services, December 2024, in the 'Two Million DBS Samples Received, Analyzed, and Reported' announcement, the company processed 436,000 dried blood spot samples in 2024 alone, marking a 33% increase within a year driven by these advanced automated analytical capabilities.

The development of quantitative dried blood spot solutions is simultaneously overcoming the hematocrit bias that historically limited clinical adoption. Manufacturers are transitioning from standard cellulose cards to volumetric absorptive microsampling (VAMS) and precise-volume devices that collect a fixed amount of blood regardless of viscosity. This technological evolution ensures that samples meet the rigorous acceptance criteria required for therapeutic drug monitoring and large-scale population studies, effectively mitigating the risk of analytical error. According to Trajan Scientific and Medical, December 2025, in the 'How Mitra microsampling went mainstream' update, a landmark 10,000-person NIH study utilizing these quantitative devices reported a sample rejection rate of less than 1%, demonstrating a level of reliability previously unattainable with traditional collection methods.

Segmental Insights

The Whatman 903 segment is positioned as the fastest-growing category within the global dried blood spot collection cards market. This expansion is primarily attributed to the extensive application of these cards in newborn screening programs and infectious disease diagnostics. Healthcare professionals rely on this specific paper type because it strictly adheres to quality specifications defined by the Clinical and Laboratory Standards Institute. Such compliance ensures consistent sample absorption and uniform distribution, which are vital for diagnostic accuracy. This proven stability during ambient transport drives the increasing preference for Whatman 903 cards across international clinical laboratories.

Regional Insights

Based on widely accepted market research, North America holds the leading share of the Global Dried Blood Spot Collection Cards Market, driven primarily by comprehensive, government-mandated newborn screening programs in the United States. The region benefits from a well-established healthcare infrastructure that actively utilizes this technology for infectious disease surveillance, toxicological analysis, and therapeutic drug monitoring. Furthermore, institutions such as the U.S. Centers for Disease Control and Prevention play a pivotal role by administering the Newborn Screening Quality Assurance Program, which ensures rigorous testing standards. This supportive regulatory environment, combined with the presence of major manufacturers, cements North America's dominance in the sector.

Recent Developments

• In February 2025, Tasso, Inc. introduced its next-generation dried blood spot sample collection technology, the Tasso Tile-T20, to support remote clinical trials and health monitoring. This new solution is designed to simplify the self-collection process for patients by integrating a painless button-activated blood collection device with a cartridge that captures four volumetrically controlled dried blood spots. The system allows for the secure shipment of samples via standard mail to laboratories for analysis. The launch targets pharmaceutical companies and researchers seeking to improve patient retention and data quality in decentralized clinical studies by removing the logistical barriers associated with venous blood draws.
• In November 2024, Capitainer announced the launch of the Capitainer SEP10, a novel dried blood spot sampling card capable of separating plasma from whole blood at the point of collection. This device utilizes microfluidic technology to automatically filter blood cells from a finger-prick sample, capturing a precise volume of plasma which then dries on the card for stable transport. By enabling the collection of high-quality plasma samples in a dried format without the need for centrifugation, the product facilitates decentralized testing for analytes that require plasma rather than whole blood, significantly expanding the utility of self-sampling in clinical diagnostics.
• In October 2024, Ahlstrom launched the Lipid Saver, a specialized specimen collection card designed to enhance the stability of fatty acids in dried blood spot samples. This new product addresses the challenge of oxidative degradation that typically affects lipid analysis in standard dried blood formats. The card features five pre-printed collection circles and is chemically treated to preserve both saturated and unsaturated fatty acids at ambient temperatures, eliminating the need for immediate refrigeration or freezing during transport. The launch aims to support the growing demand for reliable, cost-effective, and minimally invasive lipidomics research and wellness testing applications globally.
• In September 2024, Neoteryx, a brand of Trajan Scientific and Medical, collaborated with the Polaris Program to facilitate breakthrough research on the effects of spaceflight on pharmaceutical metabolism. During the Polaris Dawn mission, crew members utilized Mitra microsampling devices to self-collect dried blood samples while in orbit. This initiative aimed to study the pharmacokinetic changes of common medications, such as acetaminophen, in a microgravity environment. The collected dried blood samples were returned to Earth for analysis, demonstrating the viability of portable, user-friendly microsampling technologies for conducting complex biomedical research in extreme and remote settings without traditional phlebotomy equipment.

Key Market Players

• QIAGEN NV
• PerkinElmer, Inc.
• Shimadzu Corporation
• Pall Corporation
• Eastern Business Forms, Inc.
• Archimed Life Science GmbH
• Centogene N.V.
• F. Hoffmann-La Roche AG
• Whatman Asia Pacific Pte. Ltd.
• DBS System SA

By Application	By End User	By Region
New-born Screening (NBS) Infectious Disease Testing Therapeutic Drug Monitoring Forensics Others	Hospitals & Clinics Ambulatory Care Centers Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Dried Blood Spot Collection Cards Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Dried Blood Spot Collection Cards Market, By Application:

• New-born Screening (NBS)
• Infectious Disease Testing
• Therapeutic Drug Monitoring
• Forensics
• Others

• Dried Blood Spot Collection Cards Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

• Dried Blood Spot Collection Cards Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE